Skip to main content
. 2021 Jan 7;42(4):648–654. doi: 10.1038/s41401-020-00577-1

Fig. 1. Generation and characterization of a lung cancer model with acquired osimertinib resistance.

Fig. 1

a Schematic diagram of the generation of an H1975 cell line with acquired osimertinib resistance via continuous treatment with gradually increasing doses of osimertinib from 30 nM to 1.5 μM for 22 weeks. b Evaluation of cell proliferation by CCK8 assay in the H1975 parental cell line (H1975-S) and the cell line with acquired osimertinib resistance (H1975-OR) after treatment with osimertinib at the indicated dose for 72 h. The IC50 for each cell line is indicated in parentheses. All data are presented as the mean ± SD from at least three independent experiments. c Flow cytometric analysis of apoptosis in H1975-S and H1975-OR cells after treatment with osimertinib at the indicated dose for 48 h. d Cell survival was assessed by crystal violet staining in H1975-S and H1975-OR cells treated with osimertinib at the indicated dose for 48 h.